Bluebird Bio and Gritstone Oncology signs a Research Collaboration
Bluebird and Gritstone collaborated to research, develop and commercialize products to treat multiple cancer using cell therapies. Gritstone will provide 10 tumor-specific targets and T-cell receptors (TCRs) in certain cases
Bluebird bio will take care of development, manufacturing and commercial activities. Gritstone will utilize its technology platform to enable patient selection for clinical studies
Gritstone to receive $20M upfront and additional $10M Series C equity investment from Bluebird. Gritstone is also eligible for development, regulatory and commercial milestones payments on any therapies, and royalties on certain approved therapies
Click here to read full press release/ article | Ref:Bluebirdbio| Image: Business Wire
Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at firstname.lastname@example.org.